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HIV/AIDS is arguably the most significant health challenge facing the world today. The 2008 numbers tell the story: 33.4 million were living with HIV, 2 million people died of 
AIDS and 2.7 million people were newly infected1. Despite impressive 
scientific advances in developing over two dozen drugs to treat HIV 
infections, there is still no cure. In addition, only about one-third of 
those who need drugs have access to therapy.
In 2003, recognizing the enormity of the scientific and humanitarian 
challenge of HIV/AIDS, two-dozen leading investigators and major 
funding organizations formed the Global HIV Vaccine Enterprise2 
(the Enterprise), a voluntary alliance of independent organizations 
committed to working together to accelerate the development of an 
HIV vaccine.
At the center of the Enterprise vision is a global research agenda, 
the Scientific Strategic Plan (the Plan), a high level framework that 
represents the collective perspectives and shared accountability of 
the Enterprise Council, the Enterprise’s senior advisory body to work 
toward aligning their strategies and activities to help realize a shared 
vision for the field 3.Originally developed in 20054 and updated for 
2010, the Plan takes into account the recent advances in HIV vaccine 
research, as well as the most pressing challenges the field faces today. 
The development of the 2010 Plan has been informed by discussions 
of five targeted working groups, and consultations with the scientific 
community. The 2010 Plan5 is accompanied by the reports of the five 
Working Groups6-10, which informed its development.
In the past several years, HIV vaccine research has made significant 
progress. The 2010 Plan comes almost exactly one year after the land-
mark results of RV14411 (the Thai trial), the first time a clinical trial 
has provided proof of concept that a vaccine can reduce risk of HIV 
acquisition. In addition, there have been important laboratory and 
computational advances that address the challenge of HIV sequence 
diversity; elegant new ways of screening for novel, broadly neutral-
izing antibodies; immunological insights into the mechanisms of viral 
control in both nonhuman primates and in humans (elite controllers 
and long term nonprogressors); and a deepening understanding of 
the pathways to immune protection in preclinical models for HIV/
AIDS.
Reflecting these scientific advances, the Plan highlights the need 
to alter our view of clinical trials in several important ways. Human 
clinical efficacy trials generate an enormous wealth of biological, 
clinical and epidemiological information. Clinical trials should be 
viewed, therefore, not as the culmination of a series of basic science 
experiments but rather as an integral part of the discovery process 
itself. Because the efficacy of a vaccine candidate depends entirely on 
its ability to elicit protective, durable immune responses against the 
cognate pathogen, the Plan stresses the need for a thorough descrip-
tion and understanding of the immunological events that underlie 
these clinical outcomes. As both the five Working Groups and the 
2010 Plan emphasize, the next stage of HIV vaccine research requires 
new tools and new ways of thinking, more trials with shorter turn-
around times, bridging the gaps between basic and clinical research, 
new funders, rapid data sharing, young people, people from other 
fields and regions of the world most affected by the epidemic, and 
industry. Realizing the priorities and targets of the 2010 Plan will also 
continue to rely on the creativity and efforts of individual investiga-
tors, as well as the collaborative efforts of multidisciplinary teams 
from around the world.
We are at an exciting moment in HIV vaccine research, but the 
end of this road is not yet in sight. The 2010 Plan provides the global 
framework to move forward as rapidly as possible towards the devel-
opment of safe and effective HIV vaccines. The challenge now is to 
transform the ideas and aspirations of the Plan into concrete and 
tangible action that will drive progress. Increased and new ways of 
global collaboration, new minds and new ideas, and the expertise 
and resources of more organizations and countries working together 
as a global community are essential if we are to reach the targets in 
the 2010 Plan.
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